Medexus Pharmaceuticals to Present at the SNN Network Canada Virtual Event on Thursday, January 7, 2021
TORONTO, ON, CHICAGO, IL and MONTREAL, QC / ACCESSWIRE / January 4, 2021 / Medexus Pharmaceuticals Inc. ("Medexus" or "Company") (TSXV:MDP) (OTCQX:MEDXF), a leading specialty pharmaceutical company with a strong North American commercial platform, today announced that it will be presenting at the SNN Network Canada Virtual Event on January 7th at 2:30PM EST. Ken d'Entremont, CEO, and Roland Boivin, CFO, will be hosting the presentation and answering questions from investors.
To access the live presentation, please use the following information:
SNN Network Canada Virtual Event 2021
Date: Thursday, January 7, 2020
Time: 2:30 PM Eastern Time (11:30 AM Pacific Time)|
If you would like to book 1on1 investor meetings with Medexus, and to watch the Company's presentation, please make sure you are registered for the virtual event here: https://canada.snn.network/signup
1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.
The SNN Network Canada Virtual Event website is available here: https://canada.snn.network/
If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://canada.snn.network/agenda
News Compliments of ACCESSWIRE
About Medexus Pharmaceuticals
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company's leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B - a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative allergy medication with a unique mode of action.
SNN.Network is your multimedia financial news platform for discovery, transparency and due diligence. This is your one-stop hub to find new investment ideas, check in on watchlist, gather the most up-to-date information on the Small-, Micro-, Nano-Cap market with the goal to help you towards achieving your wealth generation goals. Follow the companies YOU want to know more about; read and watch content from YOUR favorite finance and investing influencers; create YOUR own watchlist and screen for ideas YOU'RE interested in; find out about investor conferences YOU want to attend - all here on SNN.Network.
If you would like to attend the SNN Network Virtual Investor Conference, please register here: https://conference.snn.network/signup
Name: Tina Byers
SOURCE: Medexus Pharmaceuticals via SNN Network
View source version on accesswire.com:
Released January 4, 2021